Short answer
HAEMONETICS CORP (HAE) filed an 8-K current report with the SEC on May 1, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Charles J. Dockendorff will leave Haemonetics’ Board after the 2026 Annual Meeting.
HAEMONETICS CORP 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Charles J. Dockendorff will leave Haemonetics’ Board after the 2026 Annual Meeting
- Board tenure since 2014, including Audit and Governance and Compliance Committee roles
- Departure not related to disagreement with the Company, reducing governance-risk concerns
- Committee and Board succession decisions may affect oversight continuity after the meeting
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other HAEMONETICS CORP 8-K filings
Get the next HAE 8-K as it lands
Follow HAE for push alerts, or ask the research agent what this filing means.